BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15196859)

  • 1. Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.
    Isonishi S; Niimi S; Sasaki H; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Jun; 93(3):647-52. PubMed ID: 15196859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Gynecol Oncol; 2012 Sep; 126(3):381-6. PubMed ID: 22609747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
    Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
    Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
    Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
    Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
    Yan X; An N; Jiang GQ; Gao M; Gao YN
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):298-301. PubMed ID: 18788637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
    Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
    Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.
    Lee CK; Lord S; Grunewald T; Gebski V; Hardy-Bessard AC; Sehouli J; Woie K; Heywood M; Schauer C; Vergote I; Scambia G; Ferrero A; Harter P; Pujade-Lauraine E; Friedlander M
    Gynecol Oncol; 2015 Jan; 136(1):18-24. PubMed ID: 25281492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience.
    Chun KC; Kim JJ; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
    Gynecol Obstet Invest; 2011; 72(3):208-14. PubMed ID: 21968161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.
    Bilici A; Salepci T; Dane F; Gumus M; Ustaalioglu BB; Seker M; Salman T; Turan C; Unal O; Yaylaci M
    Arch Gynecol Obstet; 2010 Oct; 282(4):417-25. PubMed ID: 20035339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
    Landrum LM; Java J; Mathews CA; Lanneau GS; Copeland LJ; Armstrong DK; Walker JL
    Gynecol Oncol; 2013 Jul; 130(1):12-8. PubMed ID: 23578540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.